Artherosclerosis Drugs is anticipated to have CAGR of ~6.2% over 2019-2028. Atherosclerosis is the condition causing narrowing of the vein as a result of plaque build-up. It causes stiffening or solidifying of the artery walls. Furthermore, the illness disturbs the stream of blood around the body, leading to cardiovascular entanglements. The awareness regarding the risk associated with the Artherosclerosis is anticipated to help the market gain lucrative growth in the forecast period. The growth in the initiatives offered by the government towards the cardiovascular diseases is expected to contribute towards a significant growth in the coming years. The drug is proved to be effective than the other drugs helping the market to gain maximum revenue shares in the next few years. However, the increased government regulations over the side effects caused by the drugs may hinder the growth.

Top Driver: Surge in the Mortality rate due to CVD to boost the industry

Artherosclerosis Drugs is projected to grow with the increase in the number of deaths caused due to the cardiovascular diseases. The steep growth in the level of low-density lipoproteins cholesterol (LDL-C), which is directly associated with atherosclerosis is anticipated to help the industry grow in the forecast period. According to the recent reports given by the Centers for Diseases Control and Prevention, about 29 million U.S. adults had elevated total cholesterol levels. Thus, the increasing level of LDL-C is attributed to propel the growth of the atherosclerosis drugs market. Furthermore, there is steep rise in the incidences of cardiac arrests, heart failures, and other cardiovascular diseases, which would lead the civil population to have awareness regarding the quality of life affected and would help the industry grow significantly in the coming years.

Hospital Pharmacies to Make Crucial Contribution to Growth of Global Artherosclerosis Drugs Market

Among distribution channel segments of the global Artherosclerosis Drugs market, Hospital Pharmacies segment is anticipated to gain maximum revenue shares in the forecast period. This owes to the rise in the patient flow through the hospitals than any other sites and hence would propel the market growth. There is steep increase in the number of in-patient and outpatients in the forecast period and also the growth in the healthcare expenditure is anticipated to help the market grow through this segment. Furthermore, the online pharmacies are anticipated to grow further due to the ease in ordering the medicines and the advancements where the timely delivery of the drugs are carried out, hence contributing to the lucrative growth of the industry in the near future.

 Surge in patient population to Benefit North American Market

North America is experiencing highest revenue growth than any other country and is anticipated to propel further in the coming years. This owes to the surge in the healthcare expenditure in the region. Furthermore, the initiatives taken by various private and government organizations to make individual aware regarding the growth in the population affected by the Artherosclerosis would boost the industry.  The growth in the research and development of drugs used to manage the condition which would help the industry to gain a lucrative growth in the near future. Asia-Pacific region is expected to experience highest CAGR, due to the increase in the investment towards improving the quality of life in the forecast period.

Due to outbreak of COVID-19 the Artherosclerosis Drugs market has experienced a downfall due to the lockout situation and unavailability of the resources. However, the growth in awareness regarding the need for having better quality of life would propel the growth of the industry.

Players to Focus on Carbapenem-based Antibiotics

The global Artherosclerosis Drugs market leaders include F. Hoffmann-La Roche Ltd, Sanofi, Bayer AG, Novartis AG, Merck & Co., Inc. (Merck Sharp & Dohme Corp), Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Mylan N.V., GlaxoSmithKline Plc., Amgen Inc., and Pfizer, Inc.

114. Hoffmann-La Roche Ltd: In February 2019, Roche and Spark Therapeutics, Inc., announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction.

Novartis AG: In January 2020, Novartis AG announced that it had completed the acquisition of The Medicines Company through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation, with and into the Company, with the Company surviving the merger, without a vote of the Company’s stockholders in accordance with Section 251(h) of the Delaware General Corporation Law.

Janssen Pharmaceutical Companies: In October 2018, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved XARELTO (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in people with chronic coronary or peripheral artery disease (CAD/PAD). XARELTO is now the first and only Factor Xa inhibitor approved for patients living with these conditions.

Scope of the Report

By Drug Class

• Cholesterol Lowering Medications
• Anti-platelet Medications
• Beta Blockers
• Others

 By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.